公开(公告)号：EP3459941A1

公开(公告)日：2019-03-27

申请号：EP17831063.7

申请日：2017-07-20

申请人： Kissei Pharmaceutical Co., Ltd.

发明人： KONDO, Atsushi ,  MORITA, Naohide ,  ISHIKAWA, Takehiro ,  YOSHIDA, Masako ,  MORIYAMA, Akihiro ,  WANAJO, Isao

IPC分类号： C07D401/14 ,  A61K31/501 ,  A61K31/506 ,  A61P9/00 ,  A61P25/06 ,  A61P43/00 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

摘要： The present invention aims to provide a novel compound which has CGRP receptor antagonist activity and which is useful for the treatment of various diseases mediated by CGRP receptors. That is, the present invention relates to the pyrrolidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In the formulae, W is ring, X is a carbon atom or the like, Y 1 to Y 4 are carbon atoms or the like, and R 1 to R 7 is alkyl or the like. The compounds of the present invention or a pharmaceutically acceptable salt thereof have an excellent CGRP receptor antagonist activity, and thus are useful as agents for the treatment of various diseases mediated by CGRP receptors.

公开(公告)号：EP4091670A1

公开(公告)日：2022-11-23

申请号：EP21767151.0

申请日：2021-03-10

申请人： KISSEI PHARMACEUTICAL CO., LTD.

发明人： TAKEUCHI, Hideki ,  KIJIMA, Yoshiro ,  MORIYAMA, Akihiro

IPC分类号： A61P1/04 ,  C07D471/04 ,  A61K31/4188

摘要： As a drug substance, a crystal having good physical properties is preferable. However, the crystal form that is most excellent as a drug substance may vary with the compound. In general, it is difficult to predict a crystal form of a drug substance having good physical properties, and it is required to variously examine each compound. Therefore, an object of the present invention is to provide a crystal having good physical properties as a drug substance for a novel compound or a salt thereof.
The present invention relates to a crystal of the compound represented by the following formula (I) or a salt thereof useful for the treatment of an inflammatory bowel disease.